Bashar Safar

Bashar Safar

Auto-generated profile, based on publicly available information

Bashar Safar

Colorectal Research Unit, Department of Surgery The Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2013 in Gastroenterology Clinics of North America
Verified
Journal Article
Closed access
ASAnkit Sarin
Ankit Sarin
BSBashar Safar
Bashar Safar

1 April 2020 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
GZGeorge Q. Zhang
George Q. Zhang
JTJames P. Taylor
James P. Taylor
MSMiloslawa Stem
Miloslawa Stem
HAHamda Almaazmi
Hamda Almaazmi
JEJonathan E. Efron
Jonathan E. Efron
BSBashar Safar
Bashar Safar
We aimed to assess patient and demographic factors, treatment trends, and survival outcomes of patients with colorectal cancer with metastasis to the liver, lung, or both sites. Differences remain among national guidelines about the optimal management strategy. Adults from the National Cancer Database (2010 to 2015) with a primary diagnosis of colorectal liver, lung, or liver and lung metastases were included and stratified by metastasis site. The primary end point was 5-year overall survival, analyzed using Kaplan-Meier survival curves, log-rank test, and the Cox proportional hazards model. Among 82,609 included patients, 70.42% had liver, 8.74% had lung, and 20.85% had simultaneous liver and lung metastases. Treatment with chemotherapy alone was used the most (21.11%), followed by chemotherapy with colorectal radical resection (CRRR) (19.4%), no treatment (14.35%), CRRR alone (9.03%), and chemotherapy with CRRR and liver/lung resection (8.22%). Patients with lung metastasis had significantly better 5-year overall survival rates than the other 2 metastatic groups (15.99%, 16.70%, and 5.51%; p < 0.001), even after stratifying by treatment type and adjusting for other factors. Chemotherapy with CRRR and liver/lung resection was associated with the greatest reduction in mortality risk for all sites in both unadjusted (35.15%, 44.52%, and 20.10%; p < 0.001) and adjusted analyses (hazard ratio 0.42; 95% CI, 0.38 to 0.47; p < 0.001; hazard ratio 0.31; 95% CI, 0.18 to 0.53; p < 0.001; and hazard ratio 0.79; 95% CI, 0.62 to 1.01; p = 0.064 for trend), and forgoing treatment or CRRR alone offered the worst overall survival. Patients with metastasis to lung had increased overall survival compared with other sites of metastases, regardless of treatment modality. Combined resection of primary tumor, metastasectomy, and chemotherapy appears to offer the greatest chance of survival.

19 June 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SESwathi Eluri
Swathi Eluri
APAlyssa M. Parian
Alyssa M. Parian
BLBerkeley N. Limketkai
Berkeley N. Limketkai
CHChristina Y. Ha
Christina Y. Ha
SBSteven R. Brant
Steven R. Brant
MLMark G. Lazarev
Mark G. Lazarev

19 August 2019 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AJAngela Y. Jia
Angela Y. Jia
ANAmol Narang
Amol Narang
BSBashar Safar
Bashar Safar
AZAtif Zaheer
Atif Zaheer
AMAdrian Murphy
Adrian Murphy
JMJeffrey Meyer
Jeffrey Meyer
There is continued debate regarding the optimal combinations of radiation therapy and chemotherapy in the preoperative treatment of locally advanced rectal adenocarcinomas. We report our single-institution experience of feasibility and early oncologic outcomes of short-course preoperative radiation therapy (5 Gy X 5 fractions) followed by consolidation neoadjuvant chemotherapy. We reviewed the records of 26 patients with locally advanced rectal adenocarcinoma. All patients underwent short course radiotherapy (5 Gy X 5 fractions) followed by chemotherapy [either modified infusional and bolus 5-fluorouracail and oxalipatin (mFOLFOX6) or capecitabine and oxaliplatin] prior to consideration for surgery. A full course of chemotherapy was defined as at least 8 weeks of chemotherapy. There were five clinical (c) T2, 16 cT3, and five cT4 rectal tumors, with 88% cN+. Twenty-five patients received a median of 4 cycles (range 3 to 8) of mFOLFOX6 (with one cycle defined as a two-week period); one patient received 3 cycles of capecitabine and oxaliplatin. All patients completed SCRT; 81% completed the full course of neoadjuvant chemotherapy with 19% requiring dose reductions in chemotherapy, most commonly due to neuropathy. Nineteen patients underwent post-treatment endoscopic evaluation, and nine patients were noted to achieve a complete clinical response (CCR). Six of the nine patients who achieved CCR opted for a non-operative approach of watch-and-wait. Twenty patients underwent surgical resection; pathologic complete response was observed in seven (35%) of these twenty. The main radiation-associated toxicity was proctitis with CTCAE Grade 2 proctitis observed in seven patients (27%). Post-operative Clavien-Dindo Grade 3 complications within 30 days of surgery were identified in six patients (30%), with no Grade 4 or 5 adverse events. Median length of hospital stay was 4.5 days (range 2–16 days); three patients were readmitted within a 30 day period. Short course preoperative radiotherapy followed by neoadjuvant chemotherapy was well-tolerated and achieved oncologic outcomes that compare favorably with short-course radiation therapy alone or long-course chemoradiotherapy. This regimen is associated with high rates of clinical and pathologic complete response.

4 September 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
CAChady Atallah
Chady Atallah
JTJames P. Taylor
James P. Taylor
BLBrian D. Lo
Brian D. Lo
MSMiloslawa Stem
Miloslawa Stem
TBTiffany Brocke
Tiffany Brocke
BSBashar Safar
Bashar Safar

15 March 2022 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
BLBrian D Bs Lo
Brian D Bs Lo
GZGeorge Q Zhang
George Q Zhang
JCJoseph K Mhs Canner
Joseph K Mhs Canner
MSMiloslawa Stem
Miloslawa Stem
JTJames P Mbbchir Taylor
James P Mbbchir Taylor
BSBashar Mbbs Safar
Bashar Mbbs Safar
BACKGROUND: The worsening opioid epidemic has led to an increased number of surgical patients with chronic preoperative opioid use. However, the impact of opioids on perioperative outcomes has yet to be fully elucidated. The purpose of this study was to assess the association between preoperative opioid dose and surgical outcomes among colectomy patients. METHODS: Adult colectomy patients in the IBM MarketScan database (2010–2017) were stratified based on preoperative opioid dose, calculated as the average opioid dose in morphine milligram equivalents (MME) in the 90 days prior to surgery: 0 MME, 1 to 49 MME, and 50 or more MME. The association between preoperative opioid dose and anastomotic leak, the primary outcome of interest, as well as other postoperative complications, was assessed using multivariable regression. RESULTS: Among 45,515 adult colectomy patients, 71.4% did not use opioids (0 MME), 27.4% had an opioid dose between 1 and 49 MME, and 1.2% had an opioid dose at or above 50 MME. Patients with preoperative opioid use exhibited a higher incidence of anastomotic leak (0 MME: 4.8%, 1–49 MME: 5.5%, ≥50 MME: 8.3%; p trend = 0.001). Multivariable analysis demonstrated a dose–response relationship between preoperative opioids and surgical outcomes, as the odds of anastomotic leak worsened with increasing opioid dose (1–49 MME: OR 1.19, 95% CI 1.08–1.31, p < 0.001; ≥50 MME: OR 1.64, 95% CI 1.20–2.24, p = 0.002). Similar dose–response relationships were seen after risk-adjustment for lung complications, pneumonia, delirium, and 30-day readmission (p < 0.05 for all). CONCLUSIONS: Providers should exercise caution when prescribing opioids preoperatively, as increasing doses of preoperative opioids were associated with worse surgical outcomes and higher 30-day readmission among adult colectomy patients.